(ALCY) Alchemy Investments Acquisition Corp 1 Company Overview

Alchemy Investments Acquisition Corp 1 is a Cayman Islands special purpose acquisition company, or SPAC, formed to raise public capital and combine with a private business. Its purpose is transactional: identify a target, negotiate a merger, secure approvals and financing, and transfer the public-company shell to an operating business.

A public acquisition vehicle, not a revenue business

The company reports one operating segment and has generated no operating revenue. Its activities consist of public-company compliance, transaction due diligence, financing work, shareholder meetings, extension payments, and the proposed merger process. The quarter ended March 31, 2026 Form 10-Q explicitly identifies Alchemy as a shell company and states that it had not commenced operations.

Before a business combination, Alchemy does not sell products or services. The trust account holds funds for public shareholders, and those investments generate interest, dividend income, and unrealized or realized gains. Those returns partly offset legal, accounting, audit, listing, insurance, administrative, and transaction costs. Sponsor loans fund cash needs outside the trust because the trust is primarily reserved for redemptions or transaction funding.

Trust-account income is not operating profitability

In FY2025, Alchemy recorded a $454,060 gain on trust investments and $11,239 of dividend income, but operating and formation costs were $1.429 million and related-party interest expense was $134,331. The result was a $1.098 million net loss. That contrasts with FY2024 net income of $4.248 million, which was driven by a $5.455 million trust-account gain rather than a profitable operating franchise. The FY2025 Form 10-K is therefore best read as a statement of transaction runway and obligations.

The March 31, 2026 quarter shows a company with a protected trust account but very limited unrestricted liquidity. It also shows that the sponsor, rather than operations, is financing the process. The quarter is more informative about deal survival than earnings momentum.

Q1 2026 costs improved, but financing pressure increased

Operating and formation costs declined to $362,994 in Q1 2026 from $401,439 in Q1 2025, a reduction of about 9.6%. That cost improvement was outweighed by lower trust-account gains and higher related-party interest. The trust gain fell to $77,816 from $124,408, dividend income fell to $731 from $3,784, and interest expense increased to $47,453 from $28,250. Net loss widened to $331,900, or $0.08 per share, from $301,497, or $0.07 per share.

The balance sheet separates trust value from corporate solvency

Total assets were $9.132 million at March 31, 2026, almost entirely represented by $8.957 million in trust investments. Current liabilities were $4.085 million, total liabilities were $9.260 million, and shareholders' deficit was $8.985 million. The $8.857 million redemption value assigned to 737,543 public shares equaled $12.01 per share. These figures explain why the auditor and management emphasize going-concern uncertainty even though the trust account remains substantial.

Alchemy's history is short, but each event materially changed the balance between trust protection, sponsor incentives, and transaction feasibility. The key lesson is that SPAC economics can change more through redemptions and deadlines than through an income statement.

1. October 2021
   Alchemy was incorporated as a blank-check company. Its original mandate allowed a broad transaction but emphasized deep technology and data analytics.
2. December 2021
   The sponsor acquired 4,312,500 founder shares for $50,000, creating the low-cost sponsor position that later shaped control and incentive analysis.
3. May 2023
   The IPO sold 11.5 million units at $10 each, generated $115.0 million of gross proceeds, and placed $116.725 million into trust after the private placement.
4. October 2024
   Shareholders approved more time, but 10,438,037 public shares were redeemed. The public float and trust resources contracted sharply.
5. August 2025
   Alchemy signed a definitive agreement with Cartiga at a proposed $540.0 million equity value, changing the story from target search to financing and closing execution.
6. September 2025
   Another 324,420 shares were redeemed for $3.791 million, leaving 737,543 public shares and approximately $8.619 million in trust immediately after redemption.
7. April-May 2026
   Nasdaq notified Alchemy that it had missed the 36-month combination deadline, and trading was suspended at the open on May 14, 2026.
8. July 2026
   A preliminary proxy proposed a September 1, 2026 meeting to seek monthly extensions through September 9, 2027, subject to sponsor contributions and shareholder approval.

Redemptions changed the capital base more than investment returns did

The annual redemption roll-forward shows 11.5 million public shares at December 31, 2023, 1,061,963 at December 31, 2024, and 737,543 at December 31, 2025. The trust value per remaining share rose from the $10 IPO price to $12.01 by March 31, 2026, but the absolute pool available for a transaction shrank dramatically. That is the central historical trade-off: stronger per-share redemption protection alongside weaker aggregate transaction funding.

The proposed combination would replace Alchemy's shell-company economics with Cartiga's operating business. Under the August 22, 2025 business combination agreement, Alchemy would domesticate into Delaware, the merger subsidiary would combine with Cartiga, and the public holding company would be renamed Cartiga Holdings, Inc. The proposed structure is an Up-C: legacy Cartiga owners would retain operating-company units paired with non-economic Class B voting shares, while public investors would hold Class A common stock in the listed parent.

Why does Cartiga fit Alchemy's original data thesis?

Alchemy initially described its search focus as deep technology centered on acquiring, processing, analyzing, and using data. Cartiga's proposed fit is not conventional software; it is a data-driven litigation-finance and legal-services investment platform. The official transaction announcement cited more than 250,000 litigation-linked fundings, relationships across more than 8,000 lawyers and law firms, over $20 million invested in IT and product development since 2020, and more than 20 years of investment experience. A March 2026 update said Cartiga had deployed more than $1.9 billion in legal-sector investments and participated in matters with more than $20 billion of estimated settlement value.

The transaction's strategic tension is funding versus dilution

The target can benefit from public currency, acquisition capacity, and a broader capital base, but Alchemy's remaining trust is not enough by itself to fund a large growth plan. The company announced that it was evaluating a PIPE to support the merger and post-closing strategy, while cautioning that no definitive financing agreements existed at that time. The March 24, 2026 PIPE announcement therefore matters more than a typical capital-markets update: financing availability may determine whether the transaction can satisfy minimum-cash needs and operate credibly after closing.

A SPAC's competitive advantage is procedural rather than product-based. Alchemy can offer a private company a negotiated path to public ownership, flexible consideration using cash and equity, an existing reporting entity, and access to public-market capital. Its sponsor and advisers also bring transaction networks. The official company site describes the vehicle as formed to complete a business combination, and the company's official website documents the original offering structure.

Competition comes from other capital routes, not only other SPACs

Alchemy competes with other SPAC sponsors for targets and financing, but also with strategic buyers, private-equity funds, continuation capital, traditional IPOs, direct listings, and private credit. Cartiga can only justify choosing this route if the structure supplies useful capital, creates acceptable dilution, preserves management incentives, and produces a credible listing. Because Alchemy's current trust is less than 2% of the proposed $540 million target equity value, its practical negotiating leverage depends heavily on sponsor support, new investors, and the target's willingness to accept equity-heavy consideration.

This scorecard is an analytical interpretation of disclosed facts, not an external rating. It highlights the core VRIO-style conclusion: Alchemy's resources are useful but not rare or difficult to imitate. Its lasting value must come from execution of the Cartiga transaction, not from the shell itself.

Ownership is unusually concentrated because most public investors redeemed while sponsor-affiliated shares remained. The latest preliminary proxy reports that Alchemy DeepTech Capital LLC beneficially owns 3,412,999 Class A shares and one Class B share and describes that block as approximately 75% of the ordinary shares. The same filing states that public holders do not appoint directors before the initial business combination and that the initial shareholders can materially influence amendments and transaction approvals.

Sponsor control is economically and strategically important

Why the incentive asymmetry matters

The sponsor originally paid $50,000 for 4,312,500 founder shares, roughly $0.01 per share before later cancellations and conversions. Public investors paid $10 per unit. That cost gap can make a completed transaction valuable to the sponsor even if post-merger performance disappoints. The 2026 preliminary proxy statement also proposes monthly extensions through September 9, 2027, funded by sponsor loans of the lesser of $30,000 or $0.03 per non-redeemed public share. That arrangement aligns the sponsor with transaction completion, but it also adds related-party claims and can prolong the period before a final outcome.

Alchemy has a strong trust value per remaining public share but a weak corporate balance sheet outside the trust. Those statements are not contradictory. The trust is ring-fenced for redemptions and transaction purposes, while accounts payable, accrued expenses, sponsor loans, and deferred underwriting fees sit against the corporate entity and become relevant to closing economics.

The going-concern warning is a funding and deadline signal

The amended annual report says Alchemy lacked an approved extension beyond September 9, 2026 at the time of that audit and did not have the capital resources needed to fund operations and complete a transaction, creating substantial doubt about its ability to continue as a going concern. The later preliminary proxy seeks to address the deadline through September 2027, but approval and monthly sponsor funding are not guaranteed. The amended FY2025 Form 10-K makes clear that this is not a routine accounting footnote.

Internal controls and listing status compound execution risk

Management concluded that disclosure controls were not effective at March 31, 2026 because of a material weakness in internal control over financial reporting. Separately, Nasdaq notified the company on April 7, 2026 that it had not completed a business combination within 36 months of the IPO registration statement's effectiveness. Trading was suspended on May 14. The Nasdaq notice filed on Form 8-K means the combined company must solve both transaction completion and future listing eligibility.

The upside case depends on a sequence of discrete milestones rather than gradual operating improvement. Alchemy needs time, financing, approvals, a workable capital structure, and a credible listing path. If those pieces align, Cartiga could gain public currency and capital to expand its asset-management model, while Alchemy shareholders would exchange shell exposure for an operating platform tied to legal-sector finance.

The most important opportunity is credible capitalization

A successful PIPE or other committed financing would improve several weaknesses at once: transaction certainty, post-closing liquidity, listing credibility, and Cartiga's ability to execute acquisitions or fund originations. The April 2026 investor presentation filing confirms that the parties were actively marketing the transaction, but presentations are not substitutes for binding capital commitments or audited merger disclosures.

Alchemy's risk profile is unusually binary. Failure to obtain an extension, complete the merger, satisfy closing conditions, raise financing, or secure an acceptable listing could end the transaction or force liquidation. Even if the combination closes, public holders face dilution from legacy target owners, sponsor economics, potential PIPE investors, warrants, fees, and any conversion of sponsor loans.

The trust account does not eliminate transaction risk

The $12.01 redemption value per public share at March 31, 2026 is an important protection, but it applies to eligible public shares under the governing documents and timing rules. It does not protect warrant holders, guarantee transaction completion, or ensure that post-merger shares retain value. It also does not solve the fact that $5.175 million of deferred underwriting fees and $2.0 million of sponsor notes are large relative to the remaining trust pool.

For Cartiga, the operating risks would become more important after closing. Legal-finance assets can have uncertain timing, adverse case outcomes, complex valuation assumptions, and regulatory sensitivity. The transaction release presents large historical deployment and settlement statistics, but those are not equivalent to audited revenue, distributable earnings, or free cash flow. Researchers should wait for the registration statement and pro forma financials before translating those figures into valuation assumptions.

A normal discounted cash flow model starts with operating revenue, margins, taxes, reinvestment, and free cash flow. That framework does not fit Alchemy as a pre-merger shell because the company has no operating revenue and its trust income is temporary. The appropriate pre-closing analysis is a probability-weighted bridge between redemption value, transaction completion, dilution, and the value of the proposed target.

The key equation is ownership-adjusted operating value

After audited merger materials are available, an analyst can value Cartiga's operating cash flows and then allocate that enterprise value across the actual pro forma capital structure. Until then, a $540 million headline equity value is only a negotiated transaction term. It does not reveal the percentage owned by current public shareholders, the cash delivered to the business, or the dilution from sponsor and financing securities.

Alchemy is best understood as a nearly fully redeemed SPAC attempting to complete a strategically plausible but financing-intensive merger with Cartiga. Its strongest asset is the protected trust value attached to the remaining public shares. Its main weakness is that the corporate entity has little unrestricted cash, substantial liabilities, concentrated sponsor control, a going-concern warning, ineffective disclosure controls, and a suspended Nasdaq listing.

The proposed Cartiga combination gives the shell a genuine operating narrative: a data-driven platform for financing legal claims and law firms, with a long investment history and substantial origination data. Yet the transaction cannot be judged from promotional scale statistics alone. The decisive documents will be the effective registration statement, audited Cartiga financials, definitive financing terms, pro forma ownership table, redemption results, and exchange-listing arrangements.